Lilly’s Zepbound wins the weight loss duel with Novo’s Wegovy
Eli Lilly has scored a win in the ongoing competition with Novo Nordisk in the obesity space, as a Phase…
All articles by Phalguni Deswal
Phalguni Deswal
@Phalguni_GD
Phalguni Deswal is reporter in the healthcare and pharmaceutical sector. With a background in medicine, Phalguni has experience working in the Indian healthcare sector. Phalguni is interested in metabolic drug therapies, digital health technologies, and drug development.
-
-
Outlook Therapeutics stock craters as the wet AMD drug fails Phase III trial
Outlook Therapeutics’ second attempt to obtain US approval for its wet age-related macular degeneration (wet AMD) therapy, Lytenava (bevacizumab-vikg) has…
-
Veeva Commercial Summit: Increased investment in medical affairs by pharma companies
Pharmaceutical companies are always looking to increase the efficiency of clinical trials, and now many of these companies are looking…
-
Kronos mulls ‘strategic alternatives’ after axing cancer drug development
Kronos Bio has discontinued the development of its last remaining clinical asset, istisociclib (KB-0742), after a review of the safety…
-
Syros stock craters after lead cancer therapy flops in Phase III trial
Syros Pharmaceuticals’ stock has declined sharply for the second time in the past three months as a Phase III trial…
-
FDA delays priority review of Neurotech’s eye cell therapy implant
Neurotech Pharmaceuticals’ eye cell therapy implant has faced a setback as the US Food and Drug Administration (FDA) has extended…
-
AstraZeneca and Amgen’s Tezspire succeeds in Phase III nasal polyps trial
AstraZeneca and Amgen have released topline data from a Phase III trial of its inflammatory therapy, Tezspire (tezepelumab) in patients…
-
DBV Technologies’ stock slides as financial woes worsens
DBV Technologies, which specialises in developing treatments for food allergies, has said that it will not have sufficient cash reserves…
-
Intra-Cellular bolsters Caplyta data with another Phase III win
Having raised the full-year sales guidance for Caplyta (lumateperone) a week ago, Intra-Cellular Therapeutics has reported positive topline data from…
-
NLS and Kadimastem stocks soar following merger agreement
Switzerland-based NLS Pharmaceutics and Israel-headquartered Kadimastem have signed a definitive merger agreement, with plans to form a joint biopharmaceutical aimed…